JPRN-jRCT2071230046招募中1 期
A phase I, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of TKT001-S following a single escalating dose administration in healthy Japanese male subjects.
Kai Megumi0 个研究点目标入组 16 人开始时间: 2023年7月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 45age old（—）
- 性别
- Male
入选标准
- •Japanese healthy males between the age of 20 to under 45 years
- •-Those who the BMI between 18.5 to under 28.0
排除标准
- •-Those with illnesses that may affect the evaluation of the drug
- •-History of hepatic, renal, or gastrointestinal or radiotherapy treatment that affects drug absorption
- •-Those with a history or suspected history of alcohol or drug abuse
研究者
相似试验
Unknown
1 期
A phase I clinical trial to study the safety tolerability, pharmacokinetics, food effect and pharmacodynamics of a new compound P7435 in in healthy, overweight and/or obese subjectsCTRI/2012/05/002691Piramal Healthcare Limited96
进行中（未招募）
1 期
Safety, tolerability, pharmacokinetics, and pharmacodynamics of single/multiple doses of IMVT-1402 in healthy participants and participants with autoimmune diseasesISRCTN11659633Immunovant Sciences GmbH168
招募中
不适用
A phase I, randomized, double-blind, placebo-controlled, single-center study designed to evaluate the safety, pharmacokinetics, and pharmacodynamic effects of single and multiple ascending doses of GDC-6599 and the effect of food on the pharmacokinetics and pharmacodynamics of GDC-6599 in healthy adult subjectsAsthma10024970NL-OMON52277Genentech, Inc.92
已完成
不适用
A phase I, double-blind, randomized, placebo-controlled, multicenter, Single- and multiple-ascending-dose study to determine initial safety, Tolerability, and pharmacokinetics of GDC-0134 in patients with amyotrophic Lateral sclerosisAmyotrophic lateral sclerosisneurodegenerative disease10029317NL-OMON46547Genentech, Inc.6
已完成
1 期
A study to evaluate the safety, tolerability, processing by the body, and response of the body to the drug VK2735 in healthy adultson-alcoholic steatohepatitis (NASH)Digestive SystemOther specified inflammatory liver diseasesISRCTN47896018Viking Therapeutics, Inc.88